DPM.F Sumitomo Dainippon Pharma Co. Ltd
- Market cap
- EUR 4.81B
- P/E
- 18.5x
- P/B
- 2.05x
- ROE
- 0.0%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 1 quarter up to Jun 2026.
Is DPM.F undervalued?
Graham numberDPM.F trades 29.7% above its Graham number.
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Sumitomo Dainippon Pharma Co. Ltd fundamental analysis
No fundamental analysis for Sumitomo Dainippon Pharma Co. Ltd yet.
Sumitomo Dainippon Pharma Co. Ltd stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Sumitomo Dainippon Pharma Co. Ltd
Sumitomo Pharma Co., Ltd. Manufactures, purchases, and sells pharmaceutical products for medical treatment in Japan, North America, and Asia. It offers therapeutic agents for parkinson's disease, type 2 diabetes, uterine fibroids and endometriosis, overactive bladder, and pediatric congenital athymia. The company also provides atypical antipsychotic, generic products, antiepileptic, atypical antipsychotic, and carbapenem antibiotic. In addition, it offers veterinary medicine…
Full company profileSumitomo Dainippon Pharma Co. Ltd financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 1 quarter up to Jun 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Sumitomo Dainippon Pharma Co. Ltd annual financial statements (JPY; K = thousand, M = million, B = billion, T = trillion)
| Item | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 412B | 467B | 459B | 483B | 516B | 560B | 556B | 315B | 399B | 453B | 51.8B |
| Gross Profit | 312B | 354B | 346B | 353B | 378B | 403B | 377B | 188B | 245B | 257B | 27.2B |
| Operating Income | 52.8B | 88.2B | 57.9B | 83.2B | 71.2B | 60.2B | -77.0B | -355B | 29.7B | 105B | 7.24B |
| EBITDA | - | 103B | 79.2B | 104B | 103B | 124B | -3.50B | -281B | 56.7B | 111B | 7.24B |
| Net Income | 29.0B | 53.4B | 48.6B | 40.8B | 56.2B | 56.4B | -74.5B | -315B | 23.6B | 107B | 0.00 |
| EPS | 73 | 135 | 122 | 103 | 142 | 142 | -188 | -793 | 59 | 269 | 0.00 |
| Balance Sheet | |||||||||||
| Total Assets | 794B | 810B | 835B | 1.25T | 1.31T | 1.31T | 1.13T | 908B | 743B | 805B | 845B |
| Total Liabilities | 333B | 357B | 337B | 621B | 660B | 634B | 728B | 751B | 573B | 512B | 436B |
| Shareholders' Equity | 461B | 453B | 498B | 529B | 581B | 608B | 407B | 156B | 169B | 292B | 409B |
| Cash & Short-term Investments | 71.4B | 148B | 137B | 102B | 194B | 203B | 143B | 29.0B | 23.1B | 44.3B | 76.6B |
| Cash Flow | |||||||||||
| Operating Cash Flow | 21.6B | 93.4B | 48.7B | 46.1B | 136B | 31.2B | 11.9B | -242B | 16.5B | - | - |
| Capital Expenditure | 8.13B | 5.13B | 9.27B | 7.72B | 6.05B | 7.35B | 12.7B | 15.7B | 13.0B | 0.00 | 0.00 |
| Free Cash Flow | - | 81.1B | 35.8B | 32.8B | 125B | 17.7B | -805M | -258B | 3.47B | - | - |
| Ratios | |||||||||||
| ROE | 6.3% | 11.8% | 9.8% | 7.7% | 9.7% | 9.3% | -18.3% | -201.8% | 13.9% | 36.5% | 0.0% |
| ROA | 3.7% | 6.6% | 5.8% | 3.3% | 4.3% | 4.3% | -6.6% | -34.7% | 3.2% | 13.3% | 0.0% |
| Net Profit Margin | 7.0% | 11.4% | 10.6% | 8.4% | 10.9% | 10.1% | -13.4% | -100.1% | 5.9% | 23.6% | 0.0% |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
Sumitomo Dainippon Pharma Co. Ltd dividends
- Dividend yield
- -
- Forward dividend
- -
- Payout ratio
- -
- Ex-dividend date
- Mar 30, 2027
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2026 | - | - | - |
| 2025 | JPY 3.00M | 0.01 | 0.0% |
| 2024 | JPY 2.79B | 7.03 | - |
| 2023 | JPY 11.1B | 28 | - |
| 2022 | JPY 11.1B | 28 | 19.7% |
| 2021 | JPY 11.1B | 28 | 19.8% |
| 2020 | EUR 13.1B | 33 | 32.2% |
| 2019 | EUR 11.1B | 28 | 22.9% |
| 2018 | EUR 7.94B | 20 | 14.9% |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Who owns Sumitomo Dainippon Pharma Co. Ltd
- Insiders 48.83%
- Institutions 22.04%
- Public & others 29.13%
- Shares outstanding 449M
- Free float 238M
Sumitomo Dainippon Pharma Co. Ltd company profile
- Company name
- Sumitomo Dainippon Pharma Co. Ltd
- Ticker
- DPM.F
- ISIN
- JP3495000006
- Exchange
- Frankfurt Exchange
- Sector
- Healthcare
- Industry
- Pharmaceuticals
- Employees
- 3,832
- Fiscal year end
- March
- Address
- 2-6-8 Doshomachi, Osaka, Japan, 541-0045
- Phone
- 81 6 6203 5321
- Website
- sumitomo-pharma.com
About Sumitomo Dainippon Pharma Co. Ltd
Sumitomo Pharma Co., Ltd. Manufactures, purchases, and sells pharmaceutical products for medical treatment in Japan, North America, and Asia. It offers therapeutic agents for parkinson's disease, type 2 diabetes, uterine fibroids and endometriosis, overactive bladder, and pediatric congenital athymia. The company also provides atypical antipsychotic, generic products, antiepileptic, atypical antipsychotic, and carbapenem antibiotic. In addition, it offers veterinary medicines, medical devices, etc. The company has collaboration and license agreement with Otsuka Pharmaceutical Co., Ltd. The company was formerly known as Sumitomo Dainippon Pharma Co., Ltd. and changed its name to Sumitomo Pharma Co., Ltd. in April 2022. The company was incorporated in 1897 and is headquartered in Osaka, Japan. Sumitomo Pharma Co., Ltd. is a subsidiary of Sumitomo Chemical Company, Limited.
Sumitomo Dainippon Pharma Co. Ltd management
10- Mr. Toru Kimura Ph.D.President, CEO & Representative Director · born 1960
- Mr. Kimihiro MizunoExecutive Officer Legal & Compliance and Intellectual Property
- Dr. Megumi MaruyamaVice President & Head of Corporate Communications
- Katsuhiko NishidaEO, SVP of S&M & Head of Japan BU Deputy
- Shunji KobayashiExecutive Officer of Human Resources
- Mr. Isao ShimizuExec. Officer, Head of Reliability Assur. Div, Dep. Head of Japan BU & Gen. Supv. of Mfg. & Mktg.
- Mr. Hideyuki HaradaMng. Exe. Off. of Supply Chain Div., SVP, Hd. of Supply Chain Div. & Hd. of Japan Bus. Unit
- Dr. Tsutomu Nakagawa Ph.D.Managing Executive Officer & Director · born 1968
- Ms. Yumi SatoManaging Exe. Officer of Vaccines and Adjuvants Biz Dev., Res. & Dev. Div. SVP and Head of R&D Div.
- Mr. Motoyuki SakaiEVP of Global Corp. Strategy, Fin. Admin, Ex. Aff., CG, Corp. Comm.; IT Mgmt & DA & Rep. Director · born 1961